QPPV.COM KNOWLEDGE ASSESSMENT

Potential Serious Risk to Public Health: How It Is Assessed

Test your understanding of the concepts covered by Potential Serious Risk to Public Health: How It Is Assessed.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A CMS states that the RMS assessment is unconvincing and requests more data, but does not explain how the issue could create a public-health risk. What is the most appropriate interpretation?

The statement automatically establishes an Article 29 concern The statement is sufficient because all requests for more data are legally serious The issue is currently an unresolved scientific matter rather than a substantiated Article 29 concern The issue must immediately be referred to PRAC

Question 2 of 10 A proposed warning addresses a serious risk but is too vague for prescribers to identify the relevant patients or take effective action. Why could this support an Article 29 concern?

Because any disagreement about wording is automatically an Article 29 issue Because inadequate product information may fail to communicate a clinically important risk and thereby create public-health significance Because product information is legally irrelevant to Article 29 Because a warning can never be used as a risk-management measure

Question 3 of 10 Which topic is within the possible scope of an Article 29 concern, according to the article?

Only spontaneous adverse-event reports Only clinical efficacy endpoints Safety, efficacy, quality or relevant product information, depending on the circumstances Only manufacturing deviations identified after authorisation

Question 4 of 10 What should a strong applicant response to an Article 29 concern primarily provide?

A general assertion that the RMS assessment is adequate Only a list of additional documents submitted A reasoned analysis of evidence, limitations, alternatives, clinical consequences, population relevance, benefit-risk and proposed measures A request to disregard contradictory evidence

Question 5 of 10 What is the most accurate interpretation of a formal Article 29 referral?

It is final proof that the medicine is unsafe It confirms that the applicant breached pharmacovigilance legislation It indicates that a Member State considered the regulatory position unacceptable because of a potential serious risk and that further assessment was required It means that all national authorisations are immediately withdrawn

Question 6 of 10 How should population exposure be used in assessing a potential serious risk to public health?

Exposure alone determines whether the threshold is met Exposure is irrelevant if the possible outcome is severe Exposure provides context for estimating the potential population consequences, together with plausibility, seriousness and evidence quality Only the number of patients in clinical trials should be considered

Question 7 of 10 Which statement best describes the role of benefit-risk assessment in an Article 29 concern?

A major therapeutic benefit automatically cancels any credible serious risk Benefit-risk is irrelevant once a safety concern is identified The concern should be considered in light of benefits, alternatives, exposure and whether the risk can be adequately managed Only the frequency of the risk matters

Question 8 of 10 Which sequence best reflects a defensible assessment of a potential serious risk to public health?

Legal conclusion, preferred regulatory action, evidence selection, public-health assessment Observation, scientific assessment, potential clinical consequence, public-health significance, regulatory qualification Number of reports, seriousness classification, automatic referral, benefit assessment Applicant position, final decision, retrospective justification, evidence review

Question 9 of 10 Which statement best distinguishes seriousness, severity and public-health significance?

They are interchangeable terms with the same regulatory meaning Severity describes intensity, seriousness has a defined clinical and pharmacovigilance meaning, and public-health significance is a broader population-level regulatory assessment Only severity is relevant to Article 29 A serious adverse event always constitutes a potential serious risk to public health

Question 10 of 10 What is CMDh's principal role after a qualifying MRP/DCP disagreement has been raised?

To determine automatically that the CMS is correct To provide a forum for Member States to examine the disagreement and seek agreement To replace the applicant's benefit-risk assessment To establish causality for every reported adverse event

QPPV.com

Potential Serious Risk to Public Health: How It Is Assessed

Cookie Settings